Dana Duey

Dana brings a combined 12 years of experience in therapeutic antibody development at both large and small biopharmaceutical companies. Dana was a founding member of the Ablexis research group responsible for creating the data package for validating the AlivaMab Mouse.  He was instrumental in the execution of the recovery and screening workflows that yielded therapeutic-quality AlivaMab antibodies.

Dana was part of the hybridoma group at Pfizer, Inc., in the metabolic disease group at Pfizer CovX, and a member of Pfizer Exploratory Technologies exploring cancer stem cells. At Igenica, Inc., Dana was a founding member of the hybridoma group, establishing the hybridoma platform and assay screening methods for generating their therapeutic antibody candidates. Dana served as a scientist in the antibody discovery group at NGM Biopharmaceuticals, Inc., where he worked on diverse targets utilizing the latest tools, methods, and technologies available in antibody development.

Dana received his BS in pharmacology from the University of California, Santa Barbara.